Page 282 - Read Online

Page 12 of 18 Zhang et al. Hepatoma Res 2019;5:27 I http://dx.doi.org/10.20517/2394-5079.2019.13

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Authors 2019.

REFERENCES
1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA cancer J Clin 2018;68:394-424.
2 Ma S, Chan KW, Hu L, Lee TK, Wo JY, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells.
Gastroenterology 2007;132:2542-56.
3 Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H, et al. CD44s regulates the TGF-β-mediated mesenchymal phenotype
and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res 2012;72:3414-23.
4 Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell
2008;13:153-66.
5 Yamashita T, Ji J, Budhu A, Forgues M, Yang W, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with
stem/progenitor cell features. Gastroenterology 2009;136:1012-24.
6 Lee TK, Cheung VC, Lu P, Lau EY, Ma S, et al. Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling
provides a therapeutic target for hepatocellular carcinoma. Hepatology 2014;60:179-91.
7 Park SC, Zeng C, Tschudy-Seney B, Nguyen NT, Eun JR, et al. Clonogenically Culturing and Expanding CD34+ Liver Cancer Stem
Cells in Vitro. Stem Cells Dev 2015;24:1506-14.
8 Mansuroglu T, Baumhoer D, Dudas J, Haller F, Cameron S, et al. Expression of stem cell factor receptor c-kit in human nontumoral and
tumoral hepatic cells. Eur J Gastroenterol Hepatol 2009;21:1206-11.
9 Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest
2010;120:3326-39.
10 Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, et al. CD24(+) Liver Tumor-Initiating Cells Drive Self-Renewal and Tumor Initiation
through STAT3-Mediated NANOG Regulation. Cell Stem Cell 2011;9:50-63.
11 Zhao W, Wang L, Han H, Jin K, Lin N, et al. 1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by
binding to the calcium channel α2δ1 subunit. Cancer Cell 2013;23:541-56.
12 Yang W, Wang C, Lin Y, Liu Q, Yu LX, et al. OV6 tumor-initiating cells contribute to tumor progression and invasion in human
+
hepatocellular carcinoma. J Hepatol 2012;57:613-20.
13 Li H, Cui ML, Chen TY, Xie HY, Cui Y, et al. Serum DLK1 is a potential prognostic biomarker in patients with hepatocellular carcinoma.
Tumour Biol 2015;36:8399-404.
14 Kawai T, Yasuchika K, Ishii T, Katayama H, Yoshitoshi EY, et al. Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular
Carcinoma. Clin Cancer Res 2015;21:3081-91.
15 Huch M, Dorrell C, Boj SF, van Es JH, Li VS, et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration.
Nature 2013;494:247-50.
16 Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, et al. AC133, a novel marker for human hematopoietic stem and
progenitor cells. Blood 1997;90:5002-12.
17 Corbeil D, Röper K, Hellwig A, Tavian M, Miraglia S, et al. The human AC133 hematopoietic stem cell antigen is also expressed in
epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000;275:5512-20.
18 Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation,
characterization, and molecular cloning. Blood 1997;90:5013-21.
19 Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, et al. CD133 as a biomarker for putative cancer stem cells in solid
tumours: limitations, problems and challenges. J Pathol 2013;229:355-78.
20 Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. Identification of a cancer stem cell in human brain tumors.Cancer Res
2003;63:5821-8.
21 Wang S, Xu ZY, Wang LF, Su W. CD133+ cancer stem cells in lung cancer. Front Biosci (Landmark Ed) 2013;18:447-53.
22 Chen S, Hou JH, Feng XY, Zhang XS, Zhou ZW, et al. Clinicopathologic significance of putative stem cell marker, CD44 and CD133,
in human gastric carcinoma. J Surg Oncol 2013;107:799-806.
23 Hori Y. Prominin-1 (CD133) reveals new faces of pancreatic progenitor cells and cancer stem cells: current knowledge and therapeutic